Stryker Corporation $SYK Stock Sold by Focus Advisor Solutions LLC

Focus Advisor Solutions LLC lowered its holdings in Stryker Corporation (NYSE:SYK – Free Report) by 6.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,797 shares of the medical technology company’s stock after selling 4,942 shares during the period. Focus Advisor Solutions LLC’s holdings in Stryker were worth $18,946,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Checchi Capital Advisers LLC grew its holdings in Stryker by 6.2% during the 3rd quarter. Checchi Capital Advisers LLC now owns 3,313 shares of the medical technology company’s stock worth $912,000 after acquiring an additional 192 shares in the last quarter. Bluebird Wealth Management LLC raised its holdings in shares of Stryker by 1.2% in the 3rd quarter. Bluebird Wealth Management LLC now owns 3,552 shares of the medical technology company’s stock valued at $978,000 after purchasing an additional 42 shares in the last quarter. Banco BTG Pactual S.A. acquired a new stake in shares of Stryker in the 3rd quarter valued at $380,000. Boston Partners lifted its position in shares of Stryker by 1.2% during the 3rd quarter. Boston Partners now owns 1,084,555 shares of the medical technology company’s stock worth $298,883,000 after purchasing an additional 13,357 shares during the last quarter. Finally, OneAscent Family Office LLC lifted its position in shares of Stryker by 14.5% during the 3rd quarter. OneAscent Family Office LLC now owns 1,526 shares of the medical technology company’s stock worth $420,000 after purchasing an additional 193 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 0.1%

Shares of Stryker stock opened at $317.96 on Thursday. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The company has a fifty day simple moving average of $294.10 and a 200-day simple moving average of $321.92. The stock has a market cap of $121.05 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 2.18 and a beta of 0.78. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. During the same quarter in the prior year, the business earned $3.19 earnings per share. Stryker’s revenue was up 7.6% compared to the same quarter last year. On average, equities analysts forecast that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Insider Activity

In related news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 550,000 shares of the company’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the sale, the director directly owned 1,701,375 shares of the company’s stock, valued at approximately $553,491,315. This trade represents a 24.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on SYK shares. BMO Capital Markets reiterated an “outperform” rating and set a $309.00 target price (down from $317.00) on shares of Stryker in a research note on Friday, October 30th. Needham & Company LLC cut their price target on Stryker from $418.00 to $359.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Canaccord Genuity Group downgraded Stryker from a “buy” rating to a “hold” rating and decreased their price target for the stock from $385.00 to $300.00 in a report on Friday, October 30th. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, UBS Group dropped their price objective on Stryker from $400.00 to $382.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $343.77.

Get Our Latest Analysis on SYK

About Stryker

(Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Read More

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.